Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 2/20 | 0.38 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.36 |
| ▸ | MEN1 | O00255 | 7/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | GFER | P55789 | 2/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19130846 | 0.83 | KEAP1 (0.39) | CA1CA2CA4KEAP1CES2 | |
| SCHEMBL670666 | 0.83 | CA1 (0.45) | CA1CA2CA4KEAP1CES2 | |
| SCHEMBL22833391 | 0.82 | CYP3A4 (0.40) | CA1CA2CA4KEAP1CES2 | |
| SCHEMBL4173495 | 0.82 | KDM4E (0.36) | CA1CA2CA4KEAP1CES2 | |
| SCHEMBL31727403 | 0.81 | CA1 (0.39) | CA1CA2CA4KEAP1CES2 | |
| SCHEMBL364018 | 0.79 | CA1 (0.50) | CA1CA2CA4KEAP1CES2 | |
| SCHEMBL9269430 | 0.78 | MAPT (0.44) | CA1CA2KDM4EGFERHSD17B10 | |
| SCHEMBL31041213 | 0.76 | KEAP1 (0.44) | CA1CA2CA4KEAP1CES2 | |
| SCHEMBL26162974 | 0.76 | CYP3A4 (0.42) | CA1CA2CA4CES2CES1 | |
| SCHEMBL5336692 | 0.76 | KEAP1 (0.44) | CA1CA2CA4KEAP1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113604194-A | Modified epoxy resin binder for stone and preparation method thereof | 湖南柯盛新材料有限公司 | 2021-11-05 | — | — | CN | claimed |
| CN-113583606-A | Stone binder of polyphenyl ether modified epoxy resin and preparation method thereof | 湖南柯盛新材料有限公司 | 2021-11-02 | — | — | CN | claimed |
| CN-113528068-A | Double-component stone crack sealer and preparation method thereof | 湖南柯盛新材料有限公司 | 2021-10-22 | — | — | CN | claimed |
| CN-113462338-A | Stone binder and preparation method thereof | 湖南柯盛新材料有限公司 | 2021-10-01 | — | — | CN | claimed |
| CN-113403015-A | Double-component stone binder and preparation method thereof | 湖南柯盛新材料有限公司 | 2021-09-17 | — | — | CN | claimed |
| CN-113604194-A | Modified epoxy resin binder for stone and preparation method thereof | 湖南柯盛新材料有限公司 | 2021-11-05 | — | — | CN | disclosed |
| CN-113583606-A | Stone binder of polyphenyl ether modified epoxy resin and preparation method thereof | 湖南柯盛新材料有限公司 | 2021-11-02 | — | — | CN | disclosed |
| CN-113528068-A | Double-component stone crack sealer and preparation method thereof | 湖南柯盛新材料有限公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-113462338-A | Stone binder and preparation method thereof | 湖南柯盛新材料有限公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-113403015-A | Double-component stone binder and preparation method thereof | 湖南柯盛新材料有限公司 | 2021-09-17 | — | — | CN | disclosed |
| EP-3354640-A2 | MIF INHIBITORS AND THEIR USES | Innovimmune Biotherapeutics, Inc. (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-2696682-B1 | MIF INHIBITORS AND THEIR USES | INNOVIMMUNE BIOTHERAPEUTICS INC (US) | 2018-03-21 | — | — | EP | disclosed |
| US-9133164-B2 | MIF inhibitors and their uses | INNOV88 LLC (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133164-B2 | MIF inhibitors and their uses | INNOV88 LLC (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150065480-A1 | MIF INHIBITORS AND THEIR USES | INNOVIMMUNE BIOTHERAPEUTICS, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065480-A1 | MIF INHIBITORS AND THEIR USES | INNOVIMMUNE BIOTHERAPEUTICS, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| WO-2012142498-A2 | MIF INHIBITORS AND THEIR USES | INNOVIMMUNE BIOTHERAPEUTICS, INC. (US) | 2012-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065480-A1 | MIF INHIBITORS AND THEIR USES | MIF, SERPINB1, HMGB2 | CA1 3319/4885CA2 2831/4885CA4 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.